In contrast, comparable to VEGFR1-Fc monotherapy, anti-angiogenic therapy in combination with CD47 blockade inhibited tumor regrowth and resulted in a low tumor burden (Fig. 4). This evidence concerns the gene CD47 and neoplasm.